Dr. Cheng is the sole founder, CEO and CSO of AllClev Tech, Inc.  He holds an M.D and a Ph.D. and is the sole inventor of several U.S. patent-pending artificial intelligence (AI) technologies for healthcare, medical applications, and clinical research, as well as an AI-powered device that assists individuals with disabilities.

He holds both an M.D. and a Ph.D.  Over the course of his career, he has held executive leadership roles including Chief Executive Officer (CEO), Chief Medical Officer (CMO), Chief Scientific Officer (CSO), and Senior Vice President (SVP) of Translational Medicine, working in organizations ranging from startups to global enterprises. 

Prior to his industry career, Dr. Cheng held a faculty role at University of Maryland School of Medicine, driving research in immunomodulation, within a division internationally recognized under the leadership of a former President of International Xenotransplantation Association and current Harvard University Professor.  With over 25 years of experience, he brings expertise across the drug development lifecycle, spanning clinical research, translational medicine, and R&D in oncology, vaccines, neurology, immunology, cell and gene therapy, transplantation, and cardiovascular disease. He also applies Quantum Biology to advance transformative therapies and has authored over 90 publications. 

Dr. Cheng specialized in postdoctoral research in Biochemistry and Molecular Biology at Northwestern University, Chicago, USA, under the mentorship of a member of the U.S. National Academy of Sciences (NAS).